National Institutes of Health, HHS.
The invention listed below is owned by an agency of the U.S. Government and is available for licensing as a biological material to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.
Start Further Info
FOR FURTHER INFORMATION CONTACT:
Jeffrey Thruston at 301-594-5179 or email@example.com. Licensing information may be obtained by communicating with the Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases, 5601 Fishers Lane, Rockville, MD 20852; tel. 301-496-2644. A signed Confidential Disclosure Agreement will be required to receive copies of unpublished information related to the invention.
End Further Info
Start Supplemental Information
Technology description follows:
A VSV-EBOV-Based Vaccine Against COVID-19
Description of Technology
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is the causative agent of for coronavirus disease 2019 (COVID-19). COVID-19 is characterized by fever, cough, difficulty breathing, loss of taste and smell, nausea, and sore throat. As of the fourth quarter 2020, COVID-19 is responsible for over 1.17 million deaths worldwide. As the pandemic continues to surge, the importance of a safe, affordable, and efficacious vaccine is of urgent importance. The present technology utilizes the well characterized vesicular stomatitis virus (VSV) encoding the Ebola virus (VSV-EBOV) to express additionally a codon-optimized SARS-CoV-2 spike protein. A single intranasal or intramuscular administration of the vaccine showed protective efficacy against COVID-19 in hamsters after 4 weeks. A single intramuscular injection showed protective efficacy against COVID-19 pneumonia in rhesus macaques within 10 days. The vaccine is inexpensive to replicate, elicits a high antigen-specific antibody titer within Start Printed Page 8214the host, and provides protective efficacy after a single dose.
This technology is available for licensing, as a biological material, for commercial development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
- Single dose vaccine against COVID-19
- Utilizes the established and well characterized VSV-EBOV vector
- Expresses high antigen titers within host cells
- Single dose protective efficacy against COVID-19
- Inexpensive and replicable
- In vivo/In vitro
Inventors: Andrea Marzi (NIAID), Wakako Asada (NIAID).
Licensing Contact: To license this technology, please contact Jeffrey Thruston at 301-594-5179 or firstname.lastname@example.org, and reference E-233-2017-0.
End Supplemental Information
Dated: January 19, 2021.
Deputy Director, Technology Transfer and Intellectual Property Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2021-02294 Filed 2-3-21; 8:45 am]
BILLING CODE 4140-01-P